Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0ZAGJB
ADC Name
WO2024193682A1 32G1-8H10-ADC
Synonyms
32G1-8H10-ADC
   Click to Show/Hide
Organization
XADCERA BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
Drug Status
Investigative
Antibody Name
undisclosed
Antigen Name
Trophoblast glycoprotein (TPBG)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth lnhibition value (TGl) 
29.2
%
TPBG Patient-derived Xenograft Model
Tumor Growth lnhibition value (TGl) 
62.9
%
TPBG Patient-derived Xenograft Model
Tumor Growth lnhibition value (TGl) 
96.4
%
TPBG Patient-derived Xenograft Model
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth lnhibition value (TGl) 
57
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
87.6
%
Undisclosed Undisclosed
Tumor Growth lnhibition value (TGl) 
91.9
%
Undisclosed Undisclosed
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.5044
ug/ml
CVCL_1544
Pleural epithelioid mesothelioma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) 29.20% Positive TPBG expression (TPBG+++/++)
Method Description
The patient-derived tumor firagments (2mmx2mmx2mm,TPBC positive cells constituted 19.5% of total cells and MET positive cells constituted 8.3% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 1.5mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 45.

   Click to Show/Hide
In Vivo Model TPBG Patient-derived Xenograft Model
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) 62.90% Positive TPBG expression (TPBG+++/++)
Method Description
The patient-derived tumor firagments (2mmx2mmx2mm,TPBC positive cells constituted 19.5% of total cells and MET positive cells constituted 8.3% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 3mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 45.

   Click to Show/Hide
In Vivo Model TPBG Patient-derived Xenograft Model
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl) 96.40% Positive TPBG expression (TPBG+++/++)
Method Description
The patient-derived tumor firagments (2mmx2mmx2mm,TPBG positive cells constituted 58.86% and MET positive cells constituted 24.08% of total cells) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 3mg/kg (QW&#422,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 28.

   Click to Show/Hide
In Vivo Model TPBG Patient-derived Xenograft Model
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
57%
Method Description
Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 1x106 (NCI-H1975) tumor cells, and treatmen with 1.5mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 28.
In Vivo Model NCI-H1977 xenograft model
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
87.60%
Method Description
Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 5x106 (NUGC-4) tumor cells, and treatmen with 3mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 35.
In Vivo Model NUGC-5 xenograft model
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth lnhibition value (TGl)
91.90%
Method Description
Cell line-derived xenograft models were established in B-NDG mice, by subcutaneous injection of 1x106 (NCI-H1975) tumor cells, and treatmen with 3mg/kg ADC (QW&#422,i.v.) after tumor volume about 200mm3. Determined tumor volume after the experiment, measured at day 28.
In Vivo Model NCI-H1979 xenograft model
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50)
0.5044 ug/ml
Method Description
Series diluted ADCs (maximum concentration: 20 ug/mL, 3-fold dilutions, 10 gradients)were used to treat human lung squamous carcinoma NCI-H226 5000cells cultured in a cellculture plate, and the killing activity was detected after 72 hours of incubation in IncuCyte (Sartorius AG, IncuCytee S3).
In Vitro Model Pleural epithelioid mesothelioma NCI-H226 cells CVCL_1544
References
Ref 1 Anti-TPBG/MET antibodies and uses thereof